uncorrected proof Research TJH‐2016‐0489.R1 Submitted: 20 December 2016 Accepted: 10 March 2017 FMS‐like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia (AML) Patients with Normal Karyotype; Mutation Status and Clinical and Laboratory Characteristics Narges Rezaei 1 , Nargess Arandi 1* , Behnaz Valibeigi 2 , Sezaneh Haghpanah 1 , Mehdi Khansalar 3 , Mani Ramzi 1 1 Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran 2 Department of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran 3 Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran Corresponding author: Nargess Arandi, Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; Phone: +98 7136122263; E‐mail: arandin@sums.ac.ir Financial disclosure: This study was financially supported with funds provided by Shiraz University of Medical Sciences, grant number 93‐01‐32‐ 8647. Conflicts of interest: The authors report no declarations of interest. Running title: FLT3 and NPM1 mutation in Iranian CN‐AML patients Introduction Acute myeloid leukemia (AML) is the most common hematologic malignancyies characterized by uncontrolled proliferation of hematopoietic stem cells resulting in abnormal accumulation of myeloblasts (1). Generally, based on the cytogenetic abnormalities, the prognosis of AML patients is categorized into three subgroups; good, intermediate and poor risk groups (2). However, about 50% of AML patients have normal cytogenetic (CN‐AML) feature, which represent a diverse subset of patients that and are usually classified as an intermediate risk group (3). Recently, assessment of molecular abnormalities has been provedn to be a useful